Overview

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Imatinib Mesylate
Criteria
Inclusion Criteria:

- Five patients who are on treatment of imatinib and deriving clinical benefit after
CAMN107DBR01 study termination and written informed consent obtained.

Exclusion Criteria:

- N/A.